A low-dose GLP-1 protocol is clinician-prescribed and designed to support appetite regulation and metabolic function in a sustainable maintenance zone
Why Purity Must Be The Priority While the kinetic benefits of these peptides are undeniable, there is an incredibly stark warning that must accompany this conversation
GLP-1 boosts insulin secretion from pancreatic beta cells in a glucose-dependent manner (meaning it only works when blood glucose is elevated, reducing hypoglycemia risk), suppresses glucagon secretion from pancreatic alpha cells (reducing glucose production by the liver), slows gastric emptying (prolonging satiety and reducing postprandial glucose spikes), and starts GLP-1 receptors in the brain (very the hypothalamus) to reduce appetite and food intake
Figure 2) (Neyra et al., 2020a)
If GLP-1 agonists show superior neuroprotective benefits, this could challenge the traditional treatment paradigm and support initiating therapy with GLP-1 agonists in selected patients. GLP-1 agonists have demonstrated mechanisms that include reducing neuroinflammation, enhancing cerebral glucose metabolism, and improving synaptic plasticity, Wu added
That is what their reference to "immunogenicity" means
